Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61

被引:6
作者
Patel, Siddharth M. [1 ]
Morrow, David A. [1 ]
Bellavia, Andrea [1 ]
Berg, David D. [1 ]
Bhatt, Deepak L. [2 ]
Jarolim, Petr [3 ]
Leiter, Lawrence A. [4 ]
McGuire, Darren K. [5 ,6 ]
Raz, Itamar [7 ,8 ]
Steg, P. Gabriel [9 ,10 ]
Wilding, John P. H. [11 ]
Sabatine, Marc S. [1 ]
Wiviott, Stephen D. [1 ]
Braunwald, Eugene [1 ]
Scirica, Benjamin M. [1 ]
Bohula, Erin A. [1 ,12 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, TIMI Study Grp, Div Med, Boston, MA USA
[2] Icahn Sch Med Mt Sinai Hlth Syst, Mt Sinai Heart, New York, NY USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA
[4] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[5] Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Cardiol, Dallas, TX USA
[6] Parkland Hlth & Hosp Syst, Dallas, TX USA
[7] Hebrew Univ Jerusalem, Fac Med, Diabet Unit, Dept Endocrinol & Metab,Hadassah Med Ctr, Jerusalem, Israel
[8] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[9] Univ Paris Cite, Hop Bichat, Assistance Publ Hop Paris, INSERM U 1148, Paris, France
[10] FACT French Alliance Cardiovasc Trials, Paris, France
[11] Univ Liverpool, Dept Cardiovasc & Metab Med, Liverpool, England
[12] TIMI Study Grp, 60 Fenwood Rd,Suite 7022, Boston, MA 02115 USA
关键词
Biomarkers; Obesity; Heart failure; Natriuretic peptides; Risk stratification; Clinical trials; CARDIOVASCULAR EVENTS; ATHEROSCLEROSIS RISK; OBESE-PATIENTS; ASSOCIATION; RATIONALE; COMMITTEE; DESIGN; IMPACT;
D O I
10.1002/ejhf.3118
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT-proBNP with respect to heart failure (HF) risk remains incompletely defined.Methods: Data were pooled across three randomized clinical trials enrolling predominantly patients who were overweight or obese with established cardiometabolic disease: SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61. Hospitalization for heart failure (HHF) was examined across strata of baseline BMI and NT-proBNP. The effect of dapagliflozin vs. placebo was assessed for a treatment interaction across BMI categories in patients with or without an elevated baseline NT-proBNP (>= 125 pg/mL).Results: Among 24,455 patients, the median NT-proBNP was 96 (IQR: 43-225) pg/mL and the median BMI was 33 (IQR 29-37) kg/m(2) , respectively, with 68% of patients having a BMI >= 30 kg/m(2) . There was a significant association between NT-proBNP and BMI which persisted after adjustment for all clinical variables (5.8 pg/mL lower NT-proBNP per 1 kg/m(2) higher BMI; p<0.001). Within any range of NT-proBNP, those at higher BMI had higher risk of HHF at 2 years (comparing BMI <30 vs. >= 40 kg/m(2) for NT-proBNP ranges of <125, 125-<450 and >= 450 pg/mL: 0.0% vs. 0.6%, 1.3% vs. 4.0%, and 8.1% vs. 13.8%, respectively), which persisted after multivariable adjustment (HRadj 7.47 [95% CI 3.16-17.66], HRadj 3.22 [95% CI 2.13-4.86], and HRadj 1.87 [95% CI 1.35-2.60], respectively). In DECLARE-TIMI 58, dapagliflozin vs. placebo consistently reduced HHF across BMI categories in those with an elevated NT-proBNP (p-trend for HR across BMI = 0.60), with a pattern of greater absolute risk reduction (ARR) at higher BMI (ARR for BMI <30 to >= 40 kg/m(2) : 2.2% to 4.7%; p-trend = 0.059).Conclusions: The risk of HHF varies across BMI categories for any given range of circulating NT-proBNP. These findings showcase the importance of considering BMI when applying NT-proBNP for HF risk stratification, particularly for patients with low-level elevations in NT-proBNP (125-<450 pg/mL) where there appears to be a clinically meaningful absolute and relative risk gradient. This article is protected by copyright. All rights reserved.
引用
收藏
页码:260 / 269
页数:10
相关论文
共 29 条
[1]   Gastric Bypass Surgery Elevates NT-ProBNP Levels [J].
Abrahamsson, Niclas ;
Engstrom, Britt Eden ;
Sundbom, Magnus ;
Karlsson, F. Anders .
OBESITY SURGERY, 2013, 23 (09) :1421-1426
[2]   Prediction of Incident Heart Failure in General Practice The Atherosclerosis Risk in Communities (ARIC) Study [J].
Agarwal, Sunil K. ;
Chambless, Lloyd E. ;
Ballantyne, Christie M. ;
Astor, Brad ;
Bertoni, Alain G. ;
Chang, Patricia P. ;
Folsom, Aaron R. ;
He, Max ;
Hoogeveen, Ron C. ;
Ni, Hanyu ;
Quibrera, Pedro M. ;
Rosamond, Wayne D. ;
Russell, Stuart D. ;
Shahar, Eyal ;
Heiss, Gerardo .
CIRCULATION-HEART FAILURE, 2012, 5 (04) :422-429
[3]  
Heidenreich Paul A, 2022, Circulation, V145, pe895, DOI [10.1161/CIR.0000000000001073, 10.1161/CIR.0000000000001063]
[4]   Weight Loss, Saline Loading, and the Natriuretic Peptide System [J].
Arora, Pankaj ;
Reingold, Jason ;
Baggish, Aaron ;
Guanaga, Derek P. ;
Wu, Connie ;
Ghorbani, Anahita ;
Song, Yanna ;
Chen-Tournaux, Annabel ;
Khan, Abigail May ;
Tainsh, Laurel T. ;
Buys, Emmanuel S. ;
Williams, Jonathan S. ;
Heublein, Denise M. ;
Burnett, John C. ;
Semigran, Marc J. ;
Bloch, Kenneth D. ;
Scherrer-Crosbie, Marielle ;
Newton-Cheh, Christopher ;
Kaplan, Lee M. ;
Wang, Thomas J. .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (01) :e001265
[5]   A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes [J].
Berg, David D. ;
Wiviott, Stephen D. ;
Scirica, Benjamin M. ;
Zelniker, Thomas A. ;
Goodrich, Erica L. ;
Jarolim, Petr ;
Mosenzon, Ofri ;
Cahn, Avivit ;
Bhatt, Deepak L. ;
Leiter, Lawrence A. ;
McGuire, Darren K. ;
Wilding, John P. H. ;
Johanson, Per ;
Langkilde, Anna Maria ;
Raz, Itamar ;
Braunwald, Eugene ;
Sabatine, Marc S. ;
Morrow, David A. .
DIABETES CARE, 2021, 44 (11) :2573-2581
[6]   Cardiovascular Safety of Lorcaserin in Overweigh or Obese Patients [J].
Bohula, E. A. ;
Wiviott, S. D. ;
McGuire, D. K. ;
Inzucchi, S. E. ;
Kuder, J. ;
Im, K. A. ;
Fanola, C. L. ;
Qamar, A. ;
Brown, C. ;
Budaj, A. ;
Garcia-Castillo, A. ;
Gupta, M. ;
Leiter, L. A. ;
Weissman, N. J. ;
White, H. D. ;
Patel, T. ;
Francis, B. ;
Miao, W. ;
Perdomo, C. ;
Dhadda, S. ;
Bonaca, M. P. ;
Ruff, C. T. ;
Keech, A. C. ;
Smith, S. R. ;
Sabatine, M. S. ;
Scirica, B. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (12) :1107-1117
[7]   Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial [J].
Bohula, Erin A. ;
Scirica, Benjamin M. ;
Fanola, Christina ;
Inzucchi, Silvio E. ;
Keech, Anthony ;
McGuire, Darren K. ;
Smith, Steven R. ;
Abrahamsen, Tim ;
Francis, Bruce H. ;
Miao, Wenfeng ;
Perdomo, Carlos A. ;
Satlin, Andrew ;
Wiviott, Stephen D. ;
Sabatine, Marc S. .
AMERICAN HEART JOURNAL, 2018, 202 :39-48
[8]   The Universal Definition of Heart Failure: Perspectives from Diverse Stakeholders [J].
Mentz, Robert J. ;
Lala, Anuradha .
JOURNAL OF CARDIAC FAILURE, 2021, 27 (04) :386-386
[9]   Associations among androgpens, estrogems, and natriuretic peptides in young women - Observations from the Dallas Heart Study [J].
Chang, Alice Y. ;
Abdullah, Shuaib M. ;
Jain, Tulika ;
Stanek, Harold G. ;
Das, Sandeep R. ;
McGuire, Darren K. ;
Auchus, Richard J. ;
de Lemos, James A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (01) :109-116
[10]   Evaluation of Analytical Performances and Comparison of 3 NT-proBNP Assays for Diagnosing Heart Failure [J].
Cho, Jooyoung ;
Lee, Jong-Han ;
Lee, Sang-Guk .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2023, 147 (08) :949-956